Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 383

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 383
---
 fair value of the Company’s common stock at the date of grant, as determined by the Board of Directors.

|                                     |     | Outstanding 
 Shares      |           |   |     | Weighted         
 Average Exercise 
 Price Per Share  |      |     | Weighted Average 
 Remaining        
 Contractual Life 
 (in years)       |      |
|:------------------------------------|:----|:------------|----------:|:--|:----|:-----------------|-----:|:----|:-----------------|-----:|
| Balance, December 31, 2022          |     |             | 1,138,110 |   |     | $                | 0.29 |     |                  | 8.18 |
| Options exercised                   |     |             |   (24,166 | ) |     | $                | 0.24 |     |                  |      |
| Options cancelled/forfeited/expired |     |             |  (331,445 | ) |     | $                | 0.31 |     |                  |      |
| Balance, December 31, 2023          |     |             |   782,499 |   |     | $                | 0.27 |     |                  | 6.86 |
| Exercisable                         |     |             |   651,663 |   |     | $                | 0.28 |     |                  | 6.60 |

The intrinsic value of options exercised during
the years ended December 31, 2023 and 2022 was $ and $, respectively.

F-63 CERo Therapeutics, Inc. Notes to Financial Statements

|                          |     | 2022 |       |   |
| Risk-free interest rate  |     |      |  2.28 | % |
| Expected life (in years) |     |      |  8.30 |   |
| Expected dividend yield  |     |      |   0.0 | % |
| Estimated volatility     |     |      | 71.31 | % |

| ● | The common stock expected dividend yield assumption of 0.0% is based on the Company’s history and expectation of no dividend payouts to common stock. |

| ● | The risk-free interest rate assumption is based on the U.S. Department of Treasury instruments whose term was most consistent with the expected life of the Company’s stock options. |

| ● | The expected stock price